Trials / Completed
CompletedNCT03077750
A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (actual)
- Sponsor
- Veloce BioPharma LLC · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of Topical VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum (VBP-245-MCV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VBP-245 Topical Gel | Topical application BID |
| DRUG | Vehicle | Vehicle Control With No Active Pharmaceutical Ingredients |
Timeline
- Start date
- 2017-02-27
- Primary completion
- 2018-03-30
- Completion
- 2018-04-27
- First posted
- 2017-03-13
- Last updated
- 2018-10-11
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03077750. Inclusion in this directory is not an endorsement.